Neurocrine Biosciences (NBIX) – Investment Analysts’ Recent Ratings Updates

Posted by on Oct 26th, 2026

Several brokerages have updated their recommendations and price targets on shares of Neurocrine Biosciences (NASDAQ: NBIX) in the last few weeks:

  • 10/16/2026 – Neurocrine Biosciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $204.00 price target on the stock.
  • 10/14/2026 – Neurocrine Biosciences was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
  • 10/12/2026 – Neurocrine Biosciences had its price target lowered by BMO Capital Markets from $164.00 to $150.00. They now have a “market perform” rating on the stock.
  • 10/6/2026 – Neurocrine Biosciences is now covered by Guggenheim. They set a “buy” rating and a $207.00 price target on the stock.
  • 9/29/2026 – Neurocrine Biosciences was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
  • 9/29/2026 – Neurocrine Biosciences had its price target lowered by UBS Group from $231.00 to $214.00. They now have a “buy” rating on the stock.
  • 9/16/2026 – Neurocrine Biosciences was upgraded by Mizuho to “hold”.
  • 9/11/2026 – Neurocrine Biosciences had its price target raised by Morgan Stanley from $182.00 to $183.00. They now have an “equal weight” rating on the stock.
  • 9/8/2026 – Neurocrine Biosciences was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
  • 9/8/2026 – Neurocrine Biosciences had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $198.00 price target on the stock.
  • 9/3/2026 – Neurocrine Biosciences had its price target raised by Citigroup from $249.00 to $253.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Leslie V. Norwalk sold 1,250 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $182.01, for a total value of $227,512.50. Following the completion of the sale, the director directly owned 1,588 shares in the company, valued at approximately $289,031.88. This trade represents a 44.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Boyer sold 826 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $157.45, for a total value of $130,053.70. Following the completion of the sale, the insider directly owned 8,722 shares of the company’s stock, valued at approximately $1,373,278.90. This represents a 8.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 4,387 shares of company stock worth $720,855. 4.60% of the stock is owned by insiders.

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.

Read More

Receive News & Ratings for Neurocrine Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.